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Abstract
Background: Evidence-based medicine is an important approach to avoiding care that is unlikely to benefit
patients in both the treatment and the diagnostic context. The medical evidence alone may not determine the
most appropriate care decision. Patient interests are best served when the advantages and risks of a diagnostic test
are viewed through the lens of the patient’s values. That is, the paradigm of evidence-based medicine should be
complemented by the paradigm of shared decision making.
Analysis: Diagnostic testing may offer physiological and psychological benefits. Clinicians should also discuss the
potential harms, however, which may be physiological (e.g. radiation or scarring), psychological (e.g. anxiety), and
financial (e.g. cost-sharing burdens). All three of these concerns are compounded by the risk of false positives or
incidental findings that are not serious, but which require decisions about further testing or treatment.
Conclusion: We suggest that patient-centered decision making around diagnostic testing involves a two-step
inquiry:
(1) Is the test medically appropriate? Does the available evidence documenting short- and long-term risk and benefits
support the test for its intended use, given the patient’s characteristics and symptoms?
(2) Is the test appropriate for this patient? Has the provider initiated a conversation about tradeoffs that helps the
patient evaluate whether the balance of risks and benefits is consonant with the patient’s own values and preferences?
Potential benefits and harms to consider include the physiological, the psychological, and the financial.
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The Excellence in Diagnostic Imaging Utilization Act of
2013 (H.R.3705) was introduced in the United States
Congress in December of 2013. If passed, the Act would
do three things: (1) direct professional medical societies
to define standards of appropriate use for advanced
diagnostic imaging technologies; (2) require practicing
physicians to consult clinical decision support tools
based on those standards (though not necessarily to fol-
low the recommendations); and (3) establish data collec-
tion mechanisms on adherence to standards and usage
of the decision support tools.
Like therapeutic interventions, diagnostic tests are some-
times ordered in cases where there is little likelihood of
benefit to the patient, or where the expected benefits come
with the risk of potential harms [1,2]. The Act’s re-
sponse is rooted in the tenets of evidence-based medi-
cine, seeking to reduce medically unnecessary usage of
diagnostic imaging in order to improve patient welfare
and potentially also reduce costs. These same concerns
apply more generally to other types of diagnostic test-
ing, such as blood tests and biopsies.
The medical evidence supporting a given clinical deci-
sion is only the first step of the clinical inquiry, however.
Patient interests are best served when the advantages
and risks of the test are viewed through the lens of the
patient’s values. Evidence-based medicine is by no means
antithetical to those goals, and is most effective when
complemented by the paradigm of shared decision mak-
ing. The medical community is actively working on
the challenge of integrating these two decision making
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Much of this literature describes clinical decisions in
general or focuses on treatments, and we aim to extend
that analysis to the diagnostic context. We suggest that
patient-centered decision making around diagnostic test-
ing involves a two-step inquiry:
(1) Is the test medically appropriate? Does the available
evidence documenting short- and long-term risk
and benefits support the test for its intended use,
given the patient’s characteristics and symptoms?
(2) Is the test appropriate for this patient? Has the
provider initiated a conversation about tradeoffs
that helps the patient evaluate whether the balance
of risks and benefits is consonant with the patient’s
own values and preferences?
Two paradigms: evidence-based medicine and
shared decision making
In recent decades, clinicians have faced growing pressure
to base their treatment decisions on rigorous research
rather than local custom. Proponents of evidence-based
medicine see it as a way to address unexplained geo-
graphical variance in care, improve patient wellbeing,
and potentially even curb rising health care costs [1].
The Choosing Wisely campaign has further galvanized
interest by identifying tests and interventions that are
often used in spite of evidence suggesting an overall lack
of patient benefit [1].
A much larger and more nuanced set of scenarios in-
volves decisions about diagnostic or therapeutic options
that offer potential benefits that may or may not justify
associated risks. The US Preventive Services Task Force
(USPSTF) issues recommendations about who should
receive screening and how often for these and other
tests, and they recently updated their guidelines to rec-
ommend against both PSA screening for prostate cancer
and routine mammography for breast cancer in younger
women. These changes prompted an outcry from some
physicians and from disease-specific advocacy groups,
who noted that these guidelines rely on quantitative
metrics about the “average” patient without accounting
for patient-specific preferences. A 45-year-old woman
whose close friend recently passed away from breast
cancer may feel very differently about mammography
than a 85-year-old woman with several chronic condi-
tions who would likely opt for palliative measures even
if cancer were diagnosed.
Diagnostic decision making should start with an as-
sessment of the testing options that are clinically in-
dicated for the patient’s symptoms, signs, and other
characteristics. It should not end there, however. It has
become a mantra that clinicians should “treat the pa-
tient, not the disease”. Diagnosis should be similarly
holistic: we urge clinicians to “diagnose the patient, not
the symptom”.
The shared decision making approach involves elicit-
ing patient-centered goals and values in order to reach
a treatment plan that is consistent with the patient’s
own priorities and preferences. Currently, many informed
consent conversations focus primarily on the expected
benefits of the recommended course of action. This is
particularly likely with medications or screenings that im-
part low risk compared to major surgical interventions
[4]. Under a model of shared decision making, clinicians
should carefully review the full range of potential benefits
and potential harms and what they would mean for that
particular patient’s wellbeing.
Information about patient-centered outcomes can help
patients envision their quality of life following various
interventions. In addition to the risk of medical compli-
cations, patients may want to know about expected levels
of pain, or the potential for incapacitation that would
undermine their ability to participate in work or daily ac-
tivities. Clinicians should also be mindful of patients’
financial situations. Patients with no insurance or large
cost-sharing burdens may benefit from considering upfront
the out-of-pocket costs for different care options [5].
Armed with this information, some patients may wish
to forego a procedure with a large price tag or impact on
quality of life, choosing instead to pursue a more conser-
vative treatment or to simply live with the underlying
condition [6,7].
Shared decision making for diagnostic testing
These treatment-related concerns remain relevant in the
diagnostic context, since testing is often a predicate to
treatment decisions. Before prescribing a test, clinicians
should consider talking through the possible outcomes
with the patient; it may well be that the differential
diagnosis is populated with conditions whose treatments
are unproven, unpalatable to the patient, or identical to
the recommended course of action without a definitive
diagnosis (conservative treatment as part of a “wait and
see” approach) [6].
Clinicians and patients should also consider together
several factors specific to the diagnostic decision itself
(see below list for a summary). Except in rare occasions,
tests do not themselves make patients feel better. The
potential benefits of testing derive from the possibility of
a diagnosis being made, since an accurate assessment of
patients’ complaints often facilitates effective treatment.
Aside from the potential physiological benefits gained by
therapeutic intervention, the patient may also experience
psychological benefits: worrying about symptoms can
produce stress and anxiety, [8] which can be alleviated by
ruling out a serious condition or by reaching an affirmative
diagnosis and establishing a care plan.
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Considered in Shared Decision Making for Diagnostic
Testing
Potential benefits of testing:
 Physiological: A symptomatic patient may receive a
diagnosis, thereby enabling treatment to address the
underlying condition
 ○ Consider whether the patient would actually want
to undergo the recommended treatment for the
conditions in the differential diagnosis.
 Psychological: The patient may finally get an answer
about worrying symptoms, or may rule out a
worrisome possibility.
Potential harms of testing:
 Physiological: Some tests impart medical risks, such as
radiation exposure from imaging, or complications and
scarring from biopsies or other invasive testing.
 Financial: The patient may have cost-sharing burdens.
 All three of these concerns are compounded by the
risk of false positives or incidental findings that are
not serious, but which require decisions about
further testing or treatment.
The potential harms of testing typically receive less atten-
tion in informed consent conversations, [4] but they may
matter a great deal to certain patients. Many diagnostic
procedures can have physiological effects, such as the radi-
ation exposure from imaging [9] or the risk of hemorrhagic
complications and scarring from a biopsy. Testing may also
produce anxiety through rounds of inconclusive results, or
in response to findings like tumors, which suggest the
possibility of a serious condition [8]. Finally, tests may
impose significant out-of-pocket financial costs on patients,
[5,6] in addition to the indirect costs of the time required
to return for imaging, blood draws, or tissue samples. We
note that these risks may apply even for routine diagnostic
tests for which clinicians may not seek formal informed
consent, such as blood draws.
These three distinct types of potential burdens are all
magnified by the potential for false positives or incidental
findings, [2] which require patients to make further deci-
sions about subsequent rounds of testing and treatment.
Patients may be acutely sensitive to any or all of these
potential harms. Imagine George, a single father with
low income who presents with persistent sciatica. His
doctor suggests lumbar MRI to check for disc protru-
sion. However, George faces a hefty copay, and worries
about missing time from work during his imaging
appointment. Even with a confirmed diagnosis of disc
protrusion, George would likely opt for conservative
treatment with exercises and anti-inflammatory medica-
tions over discectomy or an epidural steroid injection.
These preferences reflect his limited insurance coverage,
his desire to remain fit for work and parenting, and a
general aversion to invasive interventions. If George’s
clinician helps him fully understand the costs and bene-
fits, he may choose to forego the MRI and simply begin
conservative treatment.
We note that some health care facilities assist in ar-
ranging social services to address many of these types
of patient concerns. Providers who practice shared
decision making can proactively identify such needs by
inquiring upfront about patient preferences. This ap-
proach is preferable to discovering addressable problems
only when a patient resists the clinician’s recommenda-
tion or simply fails to complete prescribed testing and
treatments.
Shared decision making has received growing atten-
tion in recent years, particularly in the emotionally
fraught area of cancer screening. Even there, however,
patients often report that they did not discuss the trade-
offs of the full range of risks and benefits [4]. We should
not rely on patients to raise these concerns unprompted,
given generally low levels of health literacy and the long-
standing cultural power imbalances between clinicians
and patients [6]. Many patients are not informed or
assertive enough to initiate conversations about harms
and benefits, and will accept their doctor’s recommenda-
tion without pushback or further inquiry. We note that
some patients may strongly wish to defer to their
physician without a collaborative decision process. These
preferences should be respected, but we advocate that
all patients be offered the opportunity to engage in
shared decision making, [10] except in situations where
shared decisions are not possible, such as emergencies.
Decision aids have been developed to educate patients
and facilitate conversations with providers [4-6]. These
aids could potentially be incorporated into clinical deci-
sion support tools, which have traditionally relied more
on evidence-based guidance (e.g. aimed at minimizing
radiation exposure) [9] than on patient-centered goals.
Conclusion
The Excellence in Diagnostic Imaging Utilization Act re-
lies on the tenets of evidence-based medicine to address
the stubborn problem of medically inappropriate diag-
nostic testing decisions. Shared decision making is much
harder to mandate, however, since it does not depend on
externally verifiable metrics like matching a diagnosis or
biomarker to a recommended treatment. Clinical deci-
sion tools can include prompts for conversations about
patient-centered outcomes and financial burden, but it is
ultimately up to individual providers to elicit each
patient’s values and preferences to help guide decisions.
To ensure appropriate diagnostic care decisions, clini-
cians should begin by asking what tests are appropriate
in general for a patient with this set of characteristics
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test or other course of action is appropriate for this
particular patient in light of her personal goals and
preferences. Indeed, the process of deciding on a diag-
nostic test requires the same consideration and patience
necessary for determining a medical diagnosis itself.
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